- Home
- REFI vs DCTH Comparison
REFI vs DCTH Comparison
Compare REFI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | DCTH |
|---|---|---|
| Founded | 2021 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 350.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | DCTH |
|---|---|---|
| Price | $13.04 | $10.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $20.00 | ★ $22.60 |
| AVG Volume (30 Days) | 124.1K | ★ 682.8K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 15.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | 0.03 |
| Revenue | $54,287,847.00 | ★ $79,603,000.00 |
| Revenue This Year | $13.78 | $131.97 |
| Revenue Next Year | $4.07 | $38.84 |
| P/E Ratio | ★ $7.67 | $291.54 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $11.85 | $8.12 |
| 52 Week High | $16.29 | $18.23 |
Technical Indicators
Market Signals| Indicator | REFI | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 55.89 |
| Support Level | $12.66 | $9.84 |
| Resistance Level | $13.49 | $10.28 |
| Average True Range (ATR) | 0.29 | 0.45 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 52.43 | 57.50 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.